Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq:MIST) granted a total of 288,000 stock options under its 2021 Inducement Plan as a material inducement for hiring six new employees, in line with Nasdaq Listing Rule 5635(c)(4).
The options, dated July 1, 2026, have a $1.32 exercise price and four-year vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 23 | leadership change | Neutral | -0.8% | Board leadership transition with election of new chairman at peer company. |
| May 14 | conference appearance | Neutral | -5.2% | Announcement of management presentation at a BioConnect investor conference. |
| May 13 | earnings report | Neutral | -9.5% | First quarter 2026 financial results and commercial/clinical development update. |
| May 06 | earnings date notice | Neutral | +4.8% | Scheduling of first quarter 2026 results release and conference call. |
| Apr 10 | clinical program update | Neutral | +0.5% | Launch of RESET-PSVT registry to gather real-world data on CARDAMYST. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Regulatory & Risk Context
Reported short positioning is elevated enough to contribute to heightened volatility and the potential for squeeze-like moves if sentiment or liquidity conditions shift.
An effective S-3 shelf allows the company to issue up to the registered amount of securities over time, providing capital-raising flexibility that could be dilutive when utilized.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees.
The Options have a grant date of July 1, 2026, and an exercise price of
The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.
The foregoing equity award was granted as an inducement material to the employees entering into employment with Milestone, in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Milestone, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Milestone, pursuant to Nasdaq Listing Rule 5635(c)(4).
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Kevin Gardner kgardner@lifesciadvisors.com
